ÂÜÀòÂÒÂ×

Christopher Plescia is a highly experienced professional in the field of bioanalytical science and translational medicine, currently serving as Director of Bioanalytical at Ensoma since April 2024. Prior to this role, Christopher held positions including Director of Clinical Biomarkers at HOOKIPA Pharma Inc., where responsibilities encompassed clinical biomarker strategy and FDA document authorship, and Associate Director of Translational Research at Nimbus Therapeutics, managing biomarker strategy and assay development. Christopher has also contributed significantly at Rubius Therapeutics and Synlogic, focusing on biomarker discovery and assay development for oncology and immuno-oncology programs. With a strong educational foundation, including a Master of Philosophy in Cell and Molecular Biology from Mount Sinai School of Medicine and a Bachelor of Arts in Neuroscience from the University of Delaware, Christopher has amassed a diverse and impactful career in biomedical research and clinical development.